Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.
Reported portfolio value by quarter (7 quarters reported)
$1.17B in Q4 2024 → $1.33B now. Hover for any quarter.
As reported for the quarter ended June 30, 2026. Activity is the change in share count since the prior quarter's filing.
| Holding | % of portfolio | Activity | Shares | Value |
|---|---|---|---|---|
| Tango Therapeutics Inc | 25.6% | Unchanged | 10,876,219 | $340M |
| Revolution Medicines Inc | 7.1% | Unchanged | 500,000 | $93.6M |
| Abivax Sa | 6.1% | Added 203% | 605,000 | $80.6M |
| UN Uniqure Nv | 5.2% | Added 127% | 1,503,300 | $69.2M |
| Kodiak Sciences Inc | 4.3% | Added 8.6% | 1,477,600 | $57.6M |
| Kymera Therapeutics Inc | 3.7% | Added 30% | 429,100 | $49.2M |
| Definium Therapeutics Inc | 3.5% | Added 67% | 998,500 | $47M |
| Replimune Group Inc | 3.3% | Added 239% | 3,983,000 | $44.1M |
| Celcuity Inc | 3.3% | Added 85% | 416,530 | $43.6M |
| Q32 Bio Inc | 3.0% | New | 3,149,310 | $40.1M |
| Capricor Therapeutics Inc | 2.5% | Added 136% | 1,395,156 | $33.6M |
| Precigen Inc | 2.2% | Added 47% | 5,150,000 | $29.4M |
| Corcept Therapeutics Inc | 2.2% | Added 34% | 335,500 | $29.2M |
| Surrozen Inc. | 2.0% | Added 44% | 1,105,683 | $27M |
| Protagonist Therapeutics Inc | 1.6% | Unchanged | 170,000 | $20.8M |
| Vir Biotechnology Inc | 1.4% | Unchanged | 1,866,000 | $19M |
| Vaxcyte Inc | 1.4% | Unchanged | 325,000 | $18.9M |
| Urogen Pharma Ltd | 1.4% | Unchanged | 500,000 | $18.4M |
| Corvus Pharmaceuticals Inc | 1.2% | Unchanged | 1,100,000 | $16.4M |
| Ptc Therapeutics Inc | 1.2% | Unchanged | 200,000 | $16.3M |
| PP Praxis Precision Medicines I | 1.2% | Unchanged | 46,457 | $15.6M |
| Amylyx Pharmaceuticals Inc | 1.1% | Unchanged | 800,000 | $14.4M |
| Ocular Therapeutix Inc | 1.0% | Added 271% | 1,300,000 | $12.8M |
| Opus Genetics Inc | 0.9% | Added 25% | 2,815,000 | $11.6M |
| Palisade Bio Inc | 0.8% | Unchanged | 4,799,875 | $10M |
| Apogee Therapeutics Inc | 0.7% | Unchanged | 70,000 | $9.29M |
| Spyre Therapeutics Inc | 0.7% | New | 100,000 | $8.88M |
| Cogent Biosciences Inc | 0.7% | Unchanged | 225,000 | $8.71M |
| Cytokinetics Inc | 0.6% | Unchanged | 100,000 | $8.52M |
| Relay Therapeutics Inc | 0.6% | New | 450,000 | $8.42M |
| Crescent Biopharma Inc. | 0.6% | Unchanged | 453,686 | $8.17M |
| Contineum Therapeutics Inc | 0.6% | Unchanged | 494,000 | $8.1M |
| Kazia Therapeutics Ltd | 0.6% | New | 560,000 | $7.88M |
| Shattuck Labs Inc | 0.5% | New | 1,000,000 | $6.94M |
| Avalo Therapeutics Inc | 0.5% | Added 25% | 375,000 | $6.93M |
| Forte Biosciences Inc | 0.4% | New | 274,500 | $5.83M |
| Relmada Therapeutics Inc | 0.4% | Unchanged | 842,106 | $5.83M |
| Moonlake Immunotherapeutics | 0.4% | Unchanged | 275,000 | $5.35M |
| Zura Bio Ltd | 0.4% | Unchanged | 900,000 | $5.31M |
| Cybin Inc | 0.4% | Added 23% | 790,000 | $5.22M |
| Odyssey Therapeutics Inc | 0.4% | New | 275,000 | $5.15M |
| Immatics N.v | 0.4% | New | 475,000 | $4.81M |
| Faeth Therapeutics Inc | 0.3% | New | 180,505 | $4.51M |
| Structure Therapeutics Inc | 0.3% | Unchanged | 75,000 | $4.03M |
| Oric Pharmaceuticals Inc | 0.3% | Added 98% | 350,000 | $3.79M |
| An2 Therapeutics Inc | 0.3% | Unchanged | 749,035 | $3.63M |
| Neumora Therapeutics Inc. | 0.3% | New | 2,000,000 | $3.4M |
| Inovio Pharmaceuticals Inc | 0.2% | Added 20% | 2,844,994 | $3.13M |
| Allogene Therapeutics Inc | 0.2% | Trimmed 45% | 1,500,000 | $3.12M |
| Solid Biosciences Inc | 0.2% | Unchanged | 300,000 | $3M |
| Karyopharm Therapeutics Inc | 0.2% | Unchanged | 302,536 | $2.96M |
| Clene Inc | 0.2% | Unchanged | 477,515 | $2.94M |
| Sarepta Therapeutics Inc | 0.2% | Unchanged | 150,000 | $2.7M |
| Maplight Therapeutics Inc | 0.2% | New | 75,000 | $2.69M |
| Nurix Therapeutics Inc | 0.2% | Unchanged | 100,000 | $2.43M |
| Lb Pharmaceuticals Inc | 0.2% | Unchanged | 70,000 | $2.27M |
| Edesa Biotech Inc | 0.1% | New | 205,000 | $1.67M |
| Invivyd Inc | 0.1% | Unchanged | 1,500,000 | $1.31M |
| Upstream Bio Inc | 0.1% | Unchanged | 150,000 | $1.04M |
| MP Milestone Pharmaceuticals In | 0.1% | Unchanged | 666,666 | $893K |
Showing top 60 of 63 positions.
What changed each quarter, from the filings' own share counts. Largest moves first; most recent 6 quarters.
quarter ended June 30, 2026 · filed August 14, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Abivax Sa | Added | +405,000 | +$54M | 6.1% |
| Q32 Bio Inc | New | +3,149,310 | +$40.1M | 3.0% |
| UN Uniqure Nv | Added | +841,300 | +$38.8M | 5.2% |
| Replimune Group Inc | Added | +2,808,000 | +$31.1M | 3.3% |
| Celcuity Inc | Added | +191,530 | +$20M | 3.3% |
| Terns Pharmaceuticals Inc | Exited | −375,000 | −$19.8M | — |
| Capricor Therapeutics Inc | Added | +805,156 | +$19.4M | 2.5% |
| Definium Therapeutics Inc | Added | +400,000 | +$18.8M | 3.5% |
| Kymera Therapeutics Inc | Added | +100,000 | +$11.5M | 3.7% |
| Precigen Inc | Added | +1,650,000 | +$9.41M | 2.2% |
Showing the 10 largest of 33 changes.
quarter ended March 31, 2026 · filed May 15, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Vaxcyte Inc | New | +325,000 | +$18.9M | 2.5% |
| Corvus Pharmaceuticals Inc | New | +1,100,000 | +$16.1M | 2.1% |
| Cidara Therapeutics Inc | Exited | −53,000 | −$11.7M | — |
| Definium Therapeutics Inc | New | +598,500 | +$11.3M | 1.5% |
| Vir Biotechnology Inc | Added | +1,241,000 | +$11.1M | 2.2% |
| Opus Genetics Inc | New | +2,250,000 | +$10.2M | 1.3% |
| Surrozen Inc | Added | +350,168 | +$10.2M | 2.9% |
| Corcept Therapeutics Inc | New | +250,000 | +$10.1M | 1.3% |
| Revolution Medicines Inc | Added | +100,000 | +$9.73M | 6.4% |
| Kodiak Sciences Inc | Added | +225,000 | +$8.58M | 6.8% |
Showing the 10 largest of 33 changes.
quarter ended December 31, 2025 · filed February 17, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Terns Pharmaceuticals Inc | New | +375,000 | +$15.2M | 3.3% |
| PP Praxis Precision Medicines I | New | +46,457 | +$13.7M | 3.0% |
| Celcuity Inc | Added | +135,000 | +$13.5M | 4.9% |
| UN Uniqure Nv | Trimmed | −510,000 | −$12.2M | 1.5% |
| Merus N V | Exited | −120,000 | −$11.3M | — |
| Palisade Bio Inc | New | +4,799,875 | +$11.3M | 2.5% |
| Kodiak Sciences Inc | Added | +386,000 | +$10.8M | 7.0% |
| Tango Therapeutics Inc | Added | +1,104,734 | +$9.79M | 21.1% |
| Surrozen Inc | New | +416,150 | +$9.4M | 2.1% |
| Capricor Therapeutics Inc | New | +325,000 | +$9.38M | 2.1% |
Showing the 10 largest of 41 changes.
quarter ended September 30, 2025 · filed February 17, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Merus N V | Trimmed | −245,000 | −$23.1M | 3.6% |
| Revolution Medicines Inc | Trimmed | −392,977 | −$18.4M | 6.0% |
| Ptc Therapeutics Inc | New | +200,000 | +$12.3M | 3.9% |
| Cytokinetics Inc | New | +200,000 | +$11M | 3.5% |
| Abivax Sa | New | +120,000 | +$10.2M | 3.2% |
| Iteos Therapeutics Inc | Exited | −825,000 | −$8.23M | — |
| Kymera Therapeutics Inc | Trimmed | −112,910 | −$6.39M | 5.8% |
| UN Uniqure Nv | Trimmed | −99,500 | −$5.81M | 14.9% |
| Inovio Pharmaceuticals Inc | New | +2,300,000 | +$5.38M | 1.7% |
| Replimune Group Inc | Trimmed | −1,161,341 | −$4.87M | 1.4% |
Showing the 10 largest of 27 changes.
quarter ended June 30, 2025 · filed February 17, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Nuvalent Inc | Exited | −450,000 | −$31.9M | — |
| Avidity Biosciences Inc | Exited | −865,000 | −$25.5M | — |
| Anaptysbio Inc | Exited | −1,300,000 | −$24.2M | — |
| Xenon Pharmaceuticals Inc | Exited | −600,000 | −$20.1M | — |
| Revolution Medicines Inc | Trimmed | −525,000 | −$19.3M | 14.7% |
| Merus N V | Trimmed | −335,000 | −$17.6M | 9.7% |
| Apellis Pharmaceuticals Inc | Exited | −713,000 | −$15.6M | — |
| Chimerix Inc | Exited | −1,810,000 | −$15.4M | — |
| Enliven Therapeutics Inc | Exited | −671,358 | −$13.2M | — |
| Oric Pharmaceuticals Inc | Exited | −1,732,571 | −$9.67M | — |
Showing the 10 largest of 34 changes.
quarter ended March 31, 2025 · filed February 17, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Springworks Therapeutics Inc | Exited | −3,421,541 | −$124M | — |
| Revolution Medicines Inc | Trimmed | −2,961,487 | −$105M | 14.0% |
| Merus N V | Trimmed | −1,200,000 | −$50.5M | 8.9% |
| Nuvalent Inc | Trimmed | −670,192 | −$47.5M | 9.6% |
| Axsome Therapeutics Inc | Exited | −470,000 | −$39.8M | — |
| SR Scholar Rock Hldg Corp | Exited | −750,000 | −$32.4M | — |
| Tyra Biosciences Inc | Exited | −2,027,678 | −$28.2M | — |
| Avidity Biosciences Inc | Trimmed | −862,388 | −$25.5M | 7.7% |
| Arcus Biosciences Inc | Exited | −1,602,200 | −$23.9M | — |
| Geron Corp | Exited | −6,000,000 | −$21.2M | — |
Showing the 10 largest of 48 changes.
Loading...
